AstraZeneca PLC
$196.47
▲
0.35%
2026-04-22 10:12:13
www.astrazeneca.com
NYQ: AZN
Explore AstraZeneca PLC stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$305.64 B
Current Price
$196.47
52W High / Low
$15,730 / $9,651
Stock P/E
30
Book Value
$31.38
Dividend Yield
1.58%
ROCE
15.97%
ROE
22.84%
Face Value
—
EPS
$6.55
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
96,100
Beta
0.28
Debt / Equity
60.97
Current Ratio
0.94
Quick Ratio
0.72
Forward P/E
25.67
Price / Sales
5.38
Enterprise Value
$340.47 B
EV / EBITDA
17.66
EV / Revenue
5.8
Rating
Strong Buy
Target Price
$211.59
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Current ratio suggests tighter short-term liquidity.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Scilex Holding Company | $6.95 | — | $58.97 M | — | 55.67% | 39.83% | $34.27 / $3.6 | $-29.75 |
| 2. | Bristol-Myers Squibb Company | $59.38 | 17.16 | $121.36 B | 4.26% | 20.6% | 40.44% | $62.89 / $42.52 | $9.07 |
| 3. | Merck & Co., Inc. | $112.83 | 15.49 | $278.33 B | 2.9% | 20.37% | 36.88% | $125.14 / $73.31 | $21.26 |
| 4. | AbbVie Inc. | NOT FOUND | 86.59 | $360.82 B | 3.4% | 22.16% | 62.25% | $244.81 / $168.54 | $-1.85 |
| 5. | Eli Lilly and Company | $921 | 40.12 | $868.52 B | 0.75% | 38.44% | 1.01% | $1,133.95 / $623.78 | $29.66 |
| 6. | Biogen Inc. | $191.44 | 21.83 | $28.09 B | — | 9.46% | 7.39% | $202.41 / $114.66 | $124.36 |
| 7. | Nasus Pharma Ltd. | $2.86 | — | $19.29 M | — | -172.62% | 2637.84% | $9.99 / $1.98 | $0.31 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 15.5 B | 15.19 B | 14.46 B | 13.59 B | 14.89 B | — |
| Operating Profit | 2.98 B | 3.58 B | 3.51 B | 3.67 B | 2.04 B | — |
| Net Profit | 2.33 B | 2.53 B | 2.45 B | 2.92 B | 1.5 B | — |
| EPS in Rs | 1.5 | 1.63 | 1.58 | 1.88 | 0.97 | 0.91 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 58.74 B | 54.07 B | 45.81 B | 44.35 B |
| Operating Profit | 13.33 B | 10.25 B | 8.72 B | 4.51 B |
| Net Profit | 10.22 B | 7.04 B | 5.96 B | 3.29 B |
| EPS in Rs | 6.6 | 4.54 | 3.84 | 2.12 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 114.07 B | 104.03 B | 101.12 B | 96.48 B |
| Total Liabilities | 65.36 B | 63.16 B | 61.95 B | 59.42 B |
| Equity | 48.67 B | 40.79 B | 39.14 B | 37.04 B |
| Current Assets | 28.72 B | 25.83 B | 25.05 B | 22.59 B |
| Current Liabilities | 30.62 B | 27.87 B | 30.54 B | 26.29 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 14.57 B | 11.86 B | 10.35 B | 9.81 B |
| Investing CF | -6.81 B | -7.98 B | -4.06 B | -2.96 B |
| Financing CF | -7.54 B | -4 B | -6.57 B | -6.82 B |
| Free CF | 8.67 B | 7.28 B | 6.57 B | 7.24 B |
| Capex | -5.91 B | -4.59 B | -3.78 B | -2.57 B |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 18.03% | 3.29% | — | — |
| Earnings Growth % | 18.14% | 81.11% | — | — |
| Profit Margin % | 13.01% | 13% | 7.41% | — |
| Operating Margin % | 18.96% | 19.04% | 10.17% | — |
| Gross Margin % | 81.12% | 81.95% | 72.06% | — |
| EBITDA Margin % | 28.55% | 29.3% | 20.48% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-02-19 | $2.153 |
| 2025-08-08 | $1.03 |
| 2025-02-21 | $2.1 |
| 2024-08-09 | $1 |
| 2024-02-22 | $1.97 |
Stock Splits
| Date | Split |
|---|---|
| 2026-02-02 | 1:0.5 |